759. Addressing Clinical Trial Heterogeneity in Neuropsychiatric Long COVID Research: A Registry-Based Cross-Sectional Analysis of Pharmacotherapeutic Intervention Trial Designs
N Hartman, D Ivkic, M C Dorczok, I Bozic, L Reinfried, A-C Moser, G Fugger, B Ludwig, F Buchmayer, M Spies, A Weidenauer, L Bartova, COVIKET Study Group · 2026
Read 759. Addressing Clinical Trial Heterogeneity in Neuropsychiatric Long COVID Research: A Registry-Based Cross-Sectional Analysis of Pharmacotherapeutic Intervention Trial Designs by N Hartman, D Ivkic, M C Dorczok, I Bozic, L Reinfried, A-C Moser, G Fugger, B Ludwig, F Buchmayer, M Spies, A Weidenauer, L Bartova, COVIKET Study Group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13556421.txt.
Description
N Hartman and a large team map drug trial designs for neuropsychiatric long COVID in 2026. Long COVID brings many symptom clusters and a heavy burden. The brain cluster includes fatigue, poor thinking, low mood, and bad sleep.
No treatment for long COVID is yet approved. Many drug trials are running with very varied designs. The team used registry data to catalog those designs. They looked at who is enrolled, what is tested, and what outcomes count. Wide variation makes results hard to compare. Readers see why shared standards are needed before trial results can guide care.
Catalog record
| CREATOR | N Hartman, D Ivkic, M C Dorczok, I Bozic, L Reinfried, A-C Moser, G Fugger, B Ludwig, F Buchmayer, M Spies, A Weidenauer, L Bartova, COVIKET Study Group |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |